Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 25;70(12):3501–3511. doi: 10.1007/s00262-021-02941-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Comparison of cytokine release and CAR-T cell proliferation between MRD-positive patients and the patients with active disease after CAR-T cell infusion. a The incidence of CRS of all grades after CAR-T cell therapy in MRD-positive B-ALL patients (n = 14) and the patients with active disease (n = 29). b–g The peak levels of serum CRP, IL-2, IL-6, IL-8, IL-10 and ferritin in MRD-positive B-ALL patients (n = 14) or the patients with active disease (n = 29); h The peak level of CD19 CAR-T cells in peripheral blood after CAR-T cell infusion